openPR Logo
Press release

End-Stage Renal Disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Segment

04-28-2022 08:42 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

End-Stage Renal Disease Market

End-Stage Renal Disease Market

DelveInsight's "End-Stage Renal Disease - Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the End-Stage Renal Disease, historical and forecasted epidemiology as well as the End-Stage Renal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the End-Stage Renal Disease Market Report:
End-Stage Renal Disease is more common in men than women; however, statistics vary little across different regions. Based on the US Renal Data System (USRDS) annual data report, the prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%). However, in the most recent US Renal Data System, 57.8% of the patients with a new-onset ESRD were men.
According to the National Center for Chronic Disease Prevention and Health Promotion, about 15% of adults in the US are estimated to have chronic kidney disease. Chronic kidney disease can often be treated before it progresses to end-stage renal failure or leads to other health problems.

Read how the End-stage renal disease market is rising by 2032 @ https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the report:

End-Stage Renal Disease market report covers a descriptive overview and comprehensive insight of the End-Stage Renal Disease Epidemiology and End-Stage Renal Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The End-Stage Renal Disease market report provides insights on the current and emerging therapies.
End-Stage Renal Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The End-Stage Renal Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the End-Stage Renal Disease market.

Got queries? Click here to know more about the https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=kpr

End-Stage Renal Disease Overview
End-stage renal disease (ESRD) also known as end-stage renal failure is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. In this condition, kidneys are only functioning at 10-15% of their normal capacity. A patient with end-stage renal failure must receive dialysis or kidney transplantation in order to survive for more than a few weeks.
End-Stage Renal Disease Market

The dynamics of the End-Stage Renal Disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Rockwell Medical Technologies, Aronora, Dynavax Technologies, Merck, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=kpr

End-Stage Renal Disease Pipeline Therapies and Key Companies

Intravenous Triferic:Rockwell Medical Technologies
AB002: Aronora
HEPLISAV-B:Dynavax Technologies
MK-2060: Merck

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. End-Stage Renal Disease Patient Share (%) Overview at a Glance
5. End-Stage Renal Disease Market Overview at a Glance
6. End-Stage Renal Disease Disease Background and Overview
7. End-Stage Renal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of End-Stage Renal Disease
9. End-Stage Renal Disease Current Treatment and Medical Practices
10. Unmet Needs
11. End-Stage Renal Disease Emerging Therapies
12. End-Stage Renal Disease Market Outlook
13. Country-Wise End-Stage Renal Disease Market Analysis (2018-2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. End-Stage Renal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about End-Stage Renal Disease Market Outlook @ https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us:
Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release End-Stage Renal Disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Segment here

News-ID: 2613367 • Views:

More Releases from DelveInsight Business Research

Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across 7MM, Backed by 211,550 Annual Cases and 15+ Key Therapies | DelveInsight
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM with 9% CAGR Growth, states DelveInsight
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period. In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipeline Assets, According to DelveInsight
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape. DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics and Triple-Combination Therapies | DelveInsight
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The asthma market is expected to experience sustained growth over the next decade, supported by the launch of

All 5 Releases


More Releases for Renal

Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market? The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032. Renal Osteodystrophy Market Overview The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be? In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market? The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period